Aglaia Therapeutics

Aglaia Therapeutics is a biotech startup developing promising novel oncology therapies. The company aims to provide drugs that restore sensitivity to current targeted treatments for cancer patients who have developed resistance to these therapies. Aglaia Therapeutics has established a pipeline of small molecules targeting the initiation of mRNA translation, which the company acquired and developed through Pierre Fabre.